Novavax June 15th Short Interest Update

Novavax (NASDAQ:NVAX) reported a rise of 2.9% or 1,866,834 shares in its short interest. The short figure came in at 25.2% of the total floats. The average daily volume of 5,723,012 shares suggests that the days to cover 65,877,329 short positions, as on June 15,2016, will be 12. On May 31,2016, the short interest was 64,010,495 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Novavax (NASDAQ:NVAX): The stock opened at $6.53 on Friday but the bulls could not build on the opening and the stock topped out at $6.79 for the day. The stock traded down to $6.49 during the day, due to lack of any buying support eventually closed down at $6.66 with a loss of -3.62% for the day. The stock had closed at $6.91 on the previous day. The total traded volume was 6,381,334 shares.

The company shares have dropped -36.93% from its 1 Year high price. On Aug 11, 2015, the shares registered one year high at $15.01 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $5.85 and the 200 Day Moving Average price is recorded at $5.85.

Novavax (NASDAQ:NVAX) has tumbled 0.45% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 13.65% in the last four weeks. In the past week, the company has outperformed the S&P 500 by 1.2% and the outperformance has advanced to 17.09% for the last 4 weeks period.

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *